Managing ILD Risk & Radiation With Adjuvant T-DXd

In the adjuvant setting, efficacy isn’t the only priority — safety and long-term quality of life matter just as much.

This clip breaks down how patients receiving T-DXd for residual disease were monitored closely with six-week CT scans, how radiation and endocrine therapy were safely integrated, and why ILD rates remained consistent with prior T-DXd experience despite longer treatment duration.